Trevi Therapeutics Completes Enrollment for Phase 2a Chronic Cough Trial; Topline Results Expected Q1 2025

Trevi Therapeutics (Nasdaq: TRVI) has completed enrollment for its Phase 2a trial evaluating Haduvio™ (oral nalbuphine ER) for the treatment of refractory chronic cough (RCC). The trial, conducted across multiple sites in the U.K. and Canada, enrolled approximately 60 patients to assess the safety, efficacy, and dosing of Haduvio. Topline results are anticipated in the first quarter of 2025.

With no approved therapies for RCC, which impacts 2-3 million adults in the U.S., Trevi aims to address the significant unmet need for effective treatments targeting cough hypersensitivity.

The company is armed with multiple near-term milestones. Earlier this month, Trevi announced that its Phase 2b CORAL trial for chronic cough in idiopathic pulmonary fibrosis (IPF) reached 50% enrollment. The company expects results from a sample size re-estimation in December 2024, with topline results from the trial expected in the first half of 2025. Additionally, dosing in Trevi’s Human Abuse Potential (HAP) study was completed, with topline data expected in December 2024.